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Introduction: Cardiovascular diseases are the main cause of death in 
many countries. The capacity of heart disease medications to alter the 
salivary flow of the patients has been extensively discussed in the 
scientific community. 
Objective: To identify the influence of medications used by patients 
with cardiovascular diseases before heart surgery on the salivary flow 
and pH. 
Method: The study included 70 adult patients with cardiovascular 
diseases, assessing their socioeconomic profile, base cardiovascular 
diseases and medications under use, and evaluating their salivary flow 
and pH. 
Results: The mean age in the group was 50 years and 52.9% of the 
evaluated patients were male. Among the cardiovascular diseases, 
52.9% were valve diseases. A strongly reduced salivary flow was found 
in 14.3% of the patients and 32.5% used betablocker drugs. The salivary 
buffering capacity was considered normal. 
Conclusion: There was a positive association between reduced salivary 
flow and use of medications, especially the beta blocker drugs, while 
the salivary buffering capacity was normal. 
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Introdução: As doenças cardiovasculares são a principal causa de morte 
em vários países. A capacidade dos medicamentos prescritos para 
tratamento de doenças cardíacas alterar o fluxo salivar dos pacientes 
tem sido extensamente discutida na comunidade científica. 
Objetivo: Identificar a influência dos medicamentos usados por 
cardiopatas antes da cirurgia cardíaca, sobre o fluxo e o pH da saliva. 
Métodos: O estudo incluiu 70 pacientes adultos com doença cardíaca, 
no tocante à investigação do perfil socioeconômico, as doenças 
cardíacas de base, os medicamentos utilizados e a avaliação do pH e do 
fluxo salivar dos mesmos. 
Resultados: A média de idade da amostra foi de 50 anos, sendo que 
52,9% dos pacientes avaliados foram do sexo masculino. Entre as 
doenças cardíacas, 52,9% foram doenças valvulares. O fluxo salivar 
muito reduzido foi encontrado em 14,3% dos pacientes, sendo que os 
beta-bloqueadores eram utilizados por 32,5% da amostra, enquanto 
que a capacidade de tamponamento salivar foi considerada normal.  
Conclusão: Houve uma relação positiva entre a diminuição do fluxo 
salivar e uso de medicamentos, especialmente os beta-bloqueadores, 
ao tempo em que a capacidade de tamponamento da saliva foi normal. 
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Cardiovascular diseases are a group of 
important conditions that present a high degree of 
prevalence in contemporary society. Approximately 50% 
of the individuals who seek medical care in clinics and 
hospitals have one from various forms of cardiovascular 
diseases, such as ischemic coronary artery disease, 
arterial hypertension, cardiomyopathy, arrhythmia, 
congenital or rheumatic valve disease
1-3
. 
Individuals with cardiovascular diseases 
generally use multiple medications. The most frequent 
are beta-blockers, angiotensin-converting enzyme 
inhibitors (ACEI) and diuretics, all known to reduce 
salivary secretion. Antihypertensive drugs are often 
reported as responsible for dryness of the mouth. Many 
patients develop depressive symptoms when they are 
given the diagnosis of a heart disease, and some of them 
may need the prescription of antidepressants which are 
also associated with reduced salivary flow
4-7
. 
For individuals who make use of such 
substances, it is important for preventive measures to be 
taken to avoid or minimize the deleterious effects of 
reduced salivary flow. These measures may include: 
higher water intake, which in individuals with congestive 
heart failure is undesirable; lemon drops; glycerin 
solutions; artificial saliva; appropriate oral hygiene; soft-
tissue management; infection control and suspension; 
and diminution or replacement of the drugs by others 
with less severe anticholinergic effects
5,8
. 
Therefore, this study aimed to identify the 
influence of cardiovascular medications on the salivary 
flow and buffering capacity of heart disease at the 
Hospital Ana Nery, Salvador, Bahia, Brazil, in preparation 
for cardiac surgery. 
 
 
 
 
 
 
This was a cross-sectional, analytical and 
descriptive study. Seventy adult patients with 
cardiovascular diseases were evaluated prior to 
undergoing heart surgery. The study was approved by 
the Ethics Committee of Hospital of the participating 
institution.  
The data collection included socioeconomic 
information (e.g., sex, age, schooling level and family 
income; information relating to the heart disease (e.g., 
etiology, severity of the disease; history of previous heart 
surgery; systemic arterial hypertension and/or diabetes 
mellitus). 
Following this initial assessment, the patients 
were evaluated individually at the dental consultation 
office. The salivary flow test consisted in assessing the 
amount of saliva that the individual produced within a 
one-minute period. The patients were instructed to keep 
a piece of paraffinized wax, weighing 1.5 g, in their 
mouths  until  it  softened  and  then  to discard the saliva 
 
 
 
 
produced during this time. Following this, they were told 
to chew the paraffin. Over the next five minutes, the 
saliva produced was collected. At the end of this time, 
the patients were asked to stop chewing and expel the 
last of the saliva stimulated. The total volume collected 
was then measured. In cases in which a high flow velocity 
was observed, the collection time was reduced. If the 
velocity was low, the time was increased. The secretion 
velocity expressed in milliliters per minute (mL/min.) was 
classified as follows: normal velocity = 1 to 2 mL/min., 
diminished velocity = 0.7 to 0.9 mL/min. and greatly 
diminished velocity ≤ 0.7 mL/min.
9,10
. 
For the saliva buffering capacity, the saliva was 
collected, under stimulation, two hours after the last 
meal, given that the buffering capacity of saliva increases 
after food intake. Hydrochloric acid at a concentration of 
0.005% was added to this saliva. Following this, the 
saliva/acid mixture was shaken and then left to rest for 
10 minutes, at which point the pH of the mixture was 
measured by means of a HOMIS® digital pH meter (no. 
898-004). The results were classified as: normal buffering 
capacity = final pH between 5 and 7; low buffering 
capacity = final pH < 4; and borderline values = pH 
between 4 and 5
9,10
. 
The descriptive statistical analysis expressed the 
relative and absolute frequencies of the socioeconomic 
characteristics, types and severity of the heart diseases, 
medications in use, salivary pH and flow velocity. The 
ANOVA test was applied, followed by the chi-square test, 
to investigate associations between the qualitative 
variables. P values < 0.05 were assumed to be statistically 
significant. 
 
 
 
 The demographic and socio-economic data are 
summarized in Table 1. 
 Heart valvular diseases accounted for 
approximately half of the sample (52.9%), while 
individuals with coronary artery disease (CAD) accounted 
for 35.8% (Table 2). Most of the patients had not 
previously undergone heart surgery (85.7%), and most 
presented severe heart disease (81.4%). Among those 
who had undergone previous heart surgery, 7 (70%) 
were diagnosed with valvular disease and three (30%) 
with CAD. Systemic arterial hypertension was present in 
41 patients (58.5%), while diabetes mellitus was found in 
16 individuals (22.8%). 
Among the medications most used by these 
patients, the following can be highlighted (Table 3): 
anticoagulants (67.14%), diuretics (61.43%), beta-
blockers (57.14%), angiotensin-converting enzyme 
inhibitors (ACEI) (50%) and platelet antiaggregants 
(48.57%). For patients with valvular diseases, digitalis 
was the drug prescribed most commonly. Individuals 
with CAD used mostly the following medications: 
vasodilators (90%), statins (87.5%), calcium antagonists 
(80%), hypoglycemic agents (72.73%), platelet 
antiaggregants (61.76%) and beta-blockers (50%).  
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Table 2. Etiology, severity of the heart diseases and history of 
prior heart surgery 
Frequency (n) (%) 
Heart disorders
a
 
         Valvular disease 
 
37 
 
52.9 
         Coronary artery disease (CAD) 25 35.8 
         Congenital cardiopathy 5 7.1 
         Valvular disease + CAD 1 1.4 
         Valvular disease + congenital 1 1.4 
         Valvular disease + CAD + 
congenital 
1 1.4 
Severity of the heart disorder
b
 
          Mild 
 
2 
 
2.9 
          Moderate 11 15.7 
          Severe 57 81.4 
Previous heart surgery
c
 
           Yes 
 
10 
 
14.3 
           No 60 85.7 
Total 70 100 
abc p = 0.000 
 
 
 
 
Normal salivary flow velocity was observed in 
most of the patients (72.8%), and the remaining 27.2% of 
the sample presented reduced flows. The difference 
between the measured velocities was considered 
statistically significant among the patients in this study, 
as shown in Table 5. 
Beta-blockers, platelet antiaggregants, statins 
and hypoglycemic agents were the main medications 
shown to be responsible for reduced saliva flow, and 70% 
of the individuals in this sample said that their level of 
liquid intake was high. The buffering capacity of saliva 
was normal. 
 
 
 
 
The results obtained from the present study 
demonstrated that there was a slightly greater 
prevalence of male patients. This finding is in agreement 
with several other studies, which reported that males 
were affected more by cardiovascular diseases. However, 
the literature suggests that post-menopausal women 
present greater cardiovascular risk than men
11
. In 2003, 
an epidemiological survey conducted by the Brazilian 
Ministry of Health, on a very heterogeneous population, 
reported greater prevalence among women
12
.
 
 There was 
no significant difference in mean family income between 
men and women; the average monthly salary was two 
minimal Brazilian wages per family. The mean age 
differed between men and women: 52.05 years for men 
versus 48.24 years for women.  
In developed countries, the most prevalent 
heart disease among adults is CAD, while in developing 
countries such as Brazil, a high prevalence of infectious 
diseases such as rheumatic fever is still observed, with a 
high rate of valvular heart disease.
13
 This explains the 
observation in the present study that valvular diseases 
were the most prevalent, followed by CAD. The patients 
with an indication for cardiac surgery were individuals 
who presented severe cardiovascular disease, for whom 
clinical treatment had been insufficient to compensate 
for the pathological condition. Thus, in the present study 
sample, 81.4% of the individuals presented severe forms 
of heart disease, while 15.7% had moderate forms. It can 
be expected that a referral hospital for cardiac diseases 
will have patients with of greater severity than the 
average hospital. 
Only 14.3% of the patients had undergone 
previous heart surgery, and 70.2% of such patients 
presented valvular disease. This higher frequency can be 
explained by the fact that surgery to change a biological 
prosthetic heart valve has a validity of 10 years, which 
makes it necessary for these patients to undergo new 
surgery to change the valve
14,15
. 
The main risk factors associated with CAD are 
systemic arterial hypertension, diabetes mellitus and 
smoking
16
. In the present study, a high prevalence of 
systemic arterial hypertension was found in 58.5% of the 
patients, while the prevalence of diabetes mellitus was 
lower (22.8%). Diabetes mellitus tends to lead to 
cardiovascular diseases and periodontal diseases.
4,17
. 
 
Table 1. Demographic and socioeconomic data. 
Characteristics (n) (%) 
Origin 
    City of Salvador – Bahia - Brazil 
 
30 
 
42.9 
I       Interior of the state of Bahia 40 57.1 
         Total 70 100 
Sex 
      Male 
 
37 
 
52.9 
      Female 33 47.1 
         Total 70 100 
Marital status 
       Single 
 
24 
 
34.3 
       Married 38 54.3 
       Divorced 01 1.4 
       Widowed 07 10 
         Total 70 100 
Age group 
        19-34 years 
 
15 
 
21.4 
 35-44 years 11 15.7 
 45-64 years 30 42.9 
 65-74 years 10 14.3 
  >75 years 4 5.7 
  Total 70 100 
Schooling 
         Illiterate 
 
7 
 
10 
         Elementary school incomplete 34 48.6 
         Elementary school completed 7 10 
         High school incomplete 2 2.9 
         High school completed 17 24.3 
         University completed 3 4.2 
         Total 70 100 
Smoking habit 
         Yes 
 
34 
 
48.6 
         No 36 51.4 
         Total 70 100 
Alcohol habit 
         Yes 
 
47 
 
67.1 
         No 23 32.9 
         Total 70 100 
Family income 
         1 and 2 minimum wage 
 
52 
 
74.3 
         3 and 4 minimum wages 15 21.4 
         5 and 6 minimum wages 03 4.3 
         Total 70 100 
 DISCUSSION 
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Table 3. Medications used by the heart disease patients. 
Medication (n) (% of Medications) (% of patients) 
Digitalis 19 27.14 5.6% 
Beta-blockers 40 57.14 11.7% 
Diuretics 43 61.43 12.6% 
Anticoagulants 47 67.14 13.8% 
Platelet antiaggregants 34 48.57 10% 
ACEI 35 50 10.3% 
Vasodilators 20 28.57 5.9% 
Aldosterone antagonist 16 22.86 4.7% 
Angiotensin II receptor blockers 14 20 4.1% 
Antiarrhythmics 4 5.71 1.2% 
Statins 24 34.29 7% 
Calcium-channel antagonists 10 14.29 2.9% 
Anxiolytics 8 11.43 2.3% 
Hypoglycemic agents 11 15.71 3.2% 
Others 16 22.86 4.7% 
Total                                                                                                341            -   - 
  
Table 4. Salivary flow velocity in patients with heart disease 
Velocity (n) (%) 
 Normal velocity (1 to 2 ml) 51 72.8 
Diminished velocity (0.7 to 0.9 ml) 9 12.9 
Greatly diminished velocity (less than 0.7 ml) 10 14.3 
Total 70 100.0 
p = 0.000 
 
 
Table 5. Medications used by the patients with heart disease and salivary flow 
Medication 
SALIVARY FLOW VELOCITY 
TOTAL 
(n) 
Normal velocity 
     (n)                (%) 
Diminished velocity 
       (n)              (%) 
Greatly diminished velocity 
     (n)                  (%) 
  Digitalis 14                  73.7 2               10.5 3                     15.8 19 
Beta-blockers 27                  67.5 6                  15 7                     17.5 40 
Diuretics 35                  81.4 3                    7 5                     11.6 43 
Anticoagulants 32                  68.1 9               19.1 6                     12.8 47 
Platelet antiaggregants 23                  67.6 8              23.5 3                       8.8 34 
ACEI 27                  77.1 3               8.6 5                     14.3 35 
Vasodilators 14                    70 5               25 1                         5 20 
Aldosterone 
antagonists 
14                  87.5 1               6.3 1                       6.3 16 
Angiotensin II receptor 
blockers 
12                  85.7 2               143 0                         0 14 
Antiarrhythmics 3                      75 0                 0 1                         25 4 
Statins 15                  62.5 6                25 3                        12.5 24 
Calcium antagonists 8                       80 1                10 1                        10 10 
Anxiolytics 7                   87.5 1              12.5 0                          0 8 
Hypoglycemic agents 7                   63.6 3              27.3 1                          9.1 11 
Others 12                   75 1                6.3 3                       18.8 16 
*Legend: (ACEI): angiotensin conversing enzyme inhibitors. 
 
 
 
 
 
Araújo et al. – Salivary Flow and Buffering Capacity in Patients with Cardiovascular Disease 
 
80 Pesq Bras Odontoped Clin Integr, João Pessoa, 13(1):77-81, jan./mar., 2013 
 
 
It has been reported that medications used for treating 
heart diseases tend to diminish saliva flow
5,7
. The 
hypoglycemic agents used by individuals with diabetes 
mellitus also reduce saliva flow
1
. In the present study, 
27.2% of the patients presented diminished saliva flow. 
The main medications correlated in this study with 
reduced saliva flow were: statins (37.5%), hypoglycemic 
agents (36.4%), beta-blockers (32.5%) and platelet 
antiaggregants (32.4%). Reduced saliva flow was 
observed in 17.5% of all beta-blocker users, similar to 
reported in the literature
5,7
. This demonstrates that 
patients using medications for systemic arterial 
hypertension, diabetes and cardiovascular diseases 
require special care, given that low levels of salivation 
are responsible for many dental and oral disorders. 
Therefore, one should give special attention particularly 
to patients using beta-blockers.  
Such patients require rigorous oral hygiene 
including thorough brushing, the use of dental floss and 
antiseptic mouthwashes, and shorter intervals between 
tooth cleanings. The use of artificial saliva, if the flow 
reduction is confirmed, has been shown to be an 
appropriate therapeutic method for controlling these 
symptoms. Also, it is important that patients, relatives 
and the healthcare team should be aware to the 
possibility of reduced salivary flow could become 
established, so that prompt action can be taken to avoid 
its adverse consequences.  
Although a slight increase in liquid intake is also 
recommended to keep the oral soft tissue hydrated, 
thereby reducing the dry-mouth feeling, patients with 
severe cardiovascular conditions typically need to restrict 
their water intake
14
. Contrary to this recommendation, in 
the present study, we found that most of the patients 
(70%) had a daily water intake that was higher than the 
level permitted representing a low adherence to the 
treatment plan
14
. The buffering capacity of the saliva was 
normal in 100% of the subjects investigated.  
 
 
 
 
The present study, conducted among patients 
prior to heart surgery, independent of the nature of the 
heart disease, showed marked reductions in saliva flow in 
relation to the use of certain medications, especially 
beta-blockers. No changes in saliva pH were observed. 
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